Same old same old…..They started a new division to fold their most promising compound into and have partnered up with mystery financiers. No disclosure of who these "partners" are or how much of a stake they now have in SBM's most valuable compound. How is something as significant like that shielded from regulatory disclosure?
No definitive news regarding Allergan, diabetes compound or pretty much anything. Didn't even mention the new staff brought on board.
So basically a typical Sirona news release (with errors and all) that creates more questions than it's answers. A+ for consistency from Howard - takes a special type of CEO to maintain such a low bar for a decade plus.